ANI Pharmaceuticals (ANIP)

[Just the facts maam]

North,

BI vs ABBV is still in play and only two of the patent argued were in the 10 related to AMGN.

BI FILES ANSWER TO ABBVIE’S COMPLAINT IN ADALIMUMAB LITIGATION

ABBVIE ANSWERS BI’S COUNTERCLAIMS IN ADALIMUMAB LITIGATION



The UK High Court declared that “the dosing regimens were obvious and are therefore not eligible for patent protection.” But equally important is how AbbVie layers overlapping patent and patent applications. Drawing out the process.

https://united-kingdom.taylorwessing.com/synapse/ti-high-court-rules-in-favour-of-fkb.html

I believe Biogen is still mulling an FDA application as well. Biogen marketing in the EU for Fuji-Samsung Bioepsis.

Like I said. I would still not take the Humira protection to 2023 in the US as a slam dunk.